AstraZeneca PLC
NASDAQ:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
NASDAQ:AZN
Watchlist
Price: 92.23 USD 0.61% Market Closed
Market Cap: $286B

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is hidden USD. Compared to the current market price of 92.23 USD, AstraZeneca PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
NASDAQ:AZN
210.3B USD 4.9 30.2 19.7 28.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.8 39.4
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR 6.8 -184.5 42.7 196.5
US
Johnson & Johnson
NYSE:JNJ
528.7B USD 5.6 19.7 13.8 16.9
CH
Roche Holding AG
SIX:ROG
275.3B CHF 4.5 29.2 12.4 14.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.2 11.9 13.9
CH
Novartis AG
SIX:NOVN
221.9B CHF 5 19.5 15.7 20.2
US
Merck & Co Inc
NYSE:MRK
267.9B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.6B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
96.5B EUR 1.4 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
UK
AstraZeneca PLC
NASDAQ:AZN
Average P/E: 23
30.2
38%
0.8
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
Negative Multiple: -184.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.2
29%
1
DK
Novo Nordisk A/S
CSE:NOVO B
17.2
2%
8.6
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
7
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average EV/EBITDA: 47.4
19.7
10%
2
US
Eli Lilly and Co
NYSE:LLY
36.8
34%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
42.7
36%
1.2
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average EV/EBIT: 111.2
28.8
23%
1.3
US
Eli Lilly and Co
NYSE:LLY
39.4
37%
1.1
UK
D
Dechra Pharmaceuticals PLC
F:1PK
196.5
98%
2
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
0%
N/A
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4